胰腺导管腺癌早期检测的影像学:筛查与监测项目实施中的更新与挑战
胰腺导管腺癌五年生存率仅12%,多数确诊时已属晚期而无法根治性切除;早期阶段因治愈性干预机会增加而预后显著更好,故早期检测对改善患者结局至关重要。本文审视当前及演变的早期检测概念、筛查策略、高危人群中的诊断产出、争议及标准影像的局限性。
要点
- 胰腺导管腺癌五年生存率仅12%,多数病例确诊时已处晚期,无法行根治性手术切除。
- 早期胰腺导管腺癌因治愈性干预可能性增加而预后显著更好,早期检测对改善患者结局至关重要。
- 本文审视早期检测概念、筛查策略、高危人群诊断产出、争议及标准影像的局限性。
核心结论
- 早期检测胰腺导管腺癌对改善患者结局至关重要,本文审视了当前及演变的早期检测概念、筛查策略、高危人群诊断产出、争议及标准影像的局限性。
研究设计与样本
- 本文为综述,检索范围与纳入文献原文未报告。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive cancers. It has a poor 5-year survival rate of 12%, partly because most cases are diagnosed at advanced stages, precluding curative surgical resection. Early-stage PDA has significantly better prognoses due to increased potential for curative interventions, making early detection of PDA critically important to improved patient outcomes. We examine current and evolving early detection concepts, screening strategies, diagnostic yields among high-risk individuals, controversies, and limitations of standard-of-care imaging.
引用
- Huang C, Hecht EM, Soloff EV, et al. Imaging for Early Detection of Pancreatic Ductal Adenocarcinoma: Updates and Challenges in the Implementation of Screening and Surveillance Programs. AJR Am J Roentgenol. 2024. PMID: 38809122. doi:10.2214/AJR.24.31151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。